| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Cancer Research United Kingdom Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS [H. J. K., R. R. R., A. L. H.] and The Henry Wellcome Building of Genomic Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7BN [R. R. R., P. J. R.], United Kingdom
| ABSTRACT |
|---|
|
|
|---|
subunits. Because these enzymes require ascorbate for activity in vitro we analyzed the effects of ascorbate on HIF in human cancer cell lines. Ascorbate at physiological concentrations (25 µM) strikingly suppressed HIF-1
protein levels and HIF transcriptional targets, particularly when the system was oncogenically activated in normoxic cells. Similar results were obtained with iron supplementation. These results indicate that both ascorbate and iron availability have major effects on HIF, and imply that the system is commonly regulated by limiting hydroxylase activity under normoxic tissue culture conditions. | Introduction |
|---|
|
|
|---|
ß heterodimeric transcription factor that directs a broad range of responses to hypoxia. The HIF transcriptional cascade is activated in cancer and plays a central role in the malignant phenotype, contributing to increased angiogenesis, enhanced glycolysis, and other properties that promote tumor growth (1)
. HIF-ß subunits are constitutive proteins, and regulation of the active complex is achieved through a multistep process affecting the abundance and activity of HIF-
subunits. HIF-
subunits are post-translationally modified by a series of oxygen-dependent enzymatic hydroxylations at specific amino acid residues (2, 3, 4, 5)
. Prolyl-4-hydroxylation at two sites within a central degradation domain by a set of closely related Fe2+ and 2-OG-dependent dioxygenases (PHD 13) mediates interactions with the VHL E3 ubiquitin ligase complex that targets HIF-
for proteasomal degradation (2
, 3)
. In a second hydroxylation-dependent control, ß-hydroxylation of an asparaginyl residue in the COOH-terminal activation domain by another Fe2+ and 2-OG-dependent dioxygenase, FIH, inhibits transcriptional activity by preventing interaction with the p300/CBP coactivator (4
, 5)
. The HIF hydroxylases are absolutely dependent on dioxygen, and limitation of activity in hypoxia allow HIF-
to escape proteolysis and become transcriptionally active. Similarly, hydroxylase inhibition by iron chelators, transition metals, and 2-OG analogues account for activation of the HIF system by these compounds (2, 3, 4, 5)
. Enzymes of this type are also known to be variably dependent on ascorbate for full catalytic activity (6)
, and ascorbate promotes HIF hydroxylase activity in vitro, raising important questions as to whether and in what way ascorbate availability affects the HIF system in the intact cell. Here we report major effects of ascorbate and iron supplementation on HIF-1
levels and the HIF transcriptional response, particularly under conditions of oncogenic activation of HIF in normoxic cells. | Materials and Methods |
|---|
|
|
|---|
Western Blotting.
Cells were homogenized in lysis buffer (6.2 M urea, 10% glycerol, 5 mM DTT, and 1% SDS plus protease inhibitors). Whole cell extract was separated by 8% SDS-PAGE and transferred to polyvinylidene difluoride membrane. Primary antibodies were mouse anti-HIF-1
monoclonals reactive to human (BD Transduction Laboratories, Lexington, KY) or mouse (Novus Biologicals, Littleton, CO) HIF-1
and a mouse anti-ß-tubulin monoclonal antibody (Sigma). Immunoreactivity was visualized with horseradish peroxidase-linked goat antimouse serum and chemiluminescence.
In Vitro Ubiquitination Assay.
HIF-1
polyubiquitylation was assayed as described previously (7)
. Briefly, [35S]methionine-labeled HIF-1
was synthesized in the presence and absence of 2 mM ascorbate (pH 7.5) by coupled transcription and translation in rabbit reticulocyte lysate (Promega, Southampton, United Kingdom).Ubiquitylation assays were performed by mixing 4 µl of 5 mg/ml ubiquitin (Sigma), 4 µl of 10x ATP regenerating system, 0.66 µl of 150 µM ubiquitin aldehyde (Affiniti Research Products, Exeter, United Kingdom), 30.5 µl of RCC4/VHL cell extract, and 2 µl of HIF-1
in vitro transcription and translation in the presence and absence of 2 mM ascorbate. The reaction mix was incubated at 30°C, and aliquots were removed into SDS sample buffer at the indicated times and analyzed by SDS-PAGE and autoradiography.
Luciferase Assay.
E48.4.51 cells were seeded at 1 x 105 cells/well in six-well plates 24 h before experimental treatments. Cells were then lysed in 400 µl of cell culture lysis reagent (Promega) before addition of luciferase assay reagent. Luminescence in relative light units was read in a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA) and normalized relative to total protein content.
RNase Protection Assay.
Total RNA was extracted in TRI Reagent (Sigma) and dissolved in hybridization buffer [80% formamide, 40 mM PIPES, 400 mM sodium chloride, and 1 mM EDTA (pH 8)]. Fifteen µg of RNA was analyzed for Glut-1 and VEGF using U6 small nuclear RNA as an internal control.
VEGF ELISA.
VEGF secretion into the culture medium was measured using a Quantikine Human VEGF Immunoassay (R&D Systems, Minneapolis, MN).
| Results |
|---|
|
|
|---|
Protein Induced by Hypoxia, Cobalt, and DFO.
in a cell line that manifests high-level induction of the protein from a low baseline level in normoxic culture. Treatment of MDA468 breast carcinoma cells with 100 µM CoCl2, 100 µM DFO, or exposure to hypoxia (0.4% O2) induced high-level expression of HIF-1
protein. In the presence of 400 µM ascorbate, levels of HIF-1
induced by DFO were reduced 3-fold, and HIF-1
induction in response to CoCl2 was inhibited completely (Fig. 1A)
induced by severe hypoxia.
|
in Normoxic Cells and Prevents Induction by Growth Factors.
in normoxic culture. We next wished to determine whether ascorbate had effects on HIF-1
expression in this situation. PC3 prostate carcinoma cells, which are functionally defective for PTEN (8)
and p53 (9)
, and demonstrate high basal levels of HIF-1
protein (10)
, were therefore exposed to ascorbate under otherwise standard conditions of normoxic tissue culture. Concentrations of ascorbate ranging from 25 to 400 µM reduced HIF-1
to undetectable levels under these conditions, indicating that concentrations well within the physiological range (approximately 2550 µM) had striking effects on the HIF system. In contrast, hypoxia-induced HIF-1
was again unaffected by even the highest dose of ascorbate (Fig. 1B)
High levels of HIF-1
can also be induced under normoxia by stimulation with specific growth factors. Both IGF-I (25 nM) and insulin (100 nM) induced HIF-1
in serum-deprived MCF7 cells. Again this stimulation of HIF-1
expression was strikingly inhibited by 25 µM ascorbate (Fig. 1E)
.
Effects of Ascorbate Are Mediated by Actions on HIF Hydroxylases.
Previously, biological requirements for ascorbate have generally been assigned to effects on the procollagen PHDs, which are required for the hydroxylation and stabilization of collagen. The current experiments suggest that, under commonly used tissue culture conditions, there are also major effects of ascorbate on the HIF hydroxylases. However, ascorbate, at least in higher concentrations, has the potential for other biochemical activities. These include generalized redox activities encompassing both reducing and oxidant effects, such as the generation of oxygen radical species by Fenton chemistry (11)
. Previous work has established that both procollagen and HIF PHDs can be powerfully inhibited by certain oxoglutarate analogues (2
, 3
, 6)
. Therefore, we hypothesized that if the action of ascorbate was via promotion of HIF PHD activity, the effects should be lost under conditions of enzyme blockade by an oxoglutarate analogue, whereas potential actions through other redox mechanisms would be unaffected. To test this we exposed PC3 cells to the oxoglutarate analogue MMOG in the presence or absence of ascorbate. As expected, 1 mM MMOG elevated HIF-1
protein levels in normoxic PC3 cells. Strikingly, ascorbate had no effect at all on HIF-1
levels under these conditions, strongly supporting an action on HIF hydroxylase activity (Fig. 2A)
. In cells that are functionally defective for VHL HIF-1
is stabilized irrespective of hydroxylation, leading to constitutively high levels of the protein. Consistent with the action of ascorbate being via hydroxylase activity, no effect was observed in VHL-defective renal carcinoma cells (Fig. 2B)
. Because hydroxylation of HIF-
promotes VHL-dependent ubiquitylation it would be predicted that promotion of hydroxylase activity by ascorbate would be manifest in in vitro assays of VHL-dependent HIF-
ubiquitylation. Data shown in Fig. 2C
indicates that this is indeed the case. Taken together these results demonstrate that the action of ascorbate is on HIF hydroxylase activity, and indicate that in pVHL-competent cells, in the absence of ascorbate supplements, HIF hydroxylase activity is limiting for HIF proteolysis under normoxic tissue culture conditions.
|
proteolysis, by iron supplementation. Addition of exogenous iron either as FeCl2 or iron-loaded transferrin, but not addition of an equimolar amount of iron-poor transferrin, strikingly reduced HIF-1
levels in normoxic PC3 cells (Fig. 2D)
by growth factors in MCF7 cells (Fig. 2E)
Effects of Ascorbate on the HIF Transcriptional Response.
To determine whether the effects of ascorbate on HIF-1
protein are reflected in the activity of the HIF transcriptional response, we analyzed effects on HRE-mediated reporter gene expression using a stably transfected Chinese hamster ovary cell line (E48.4.51) that expresses an HRE-regulated luciferase gene. Because this cell line has very low basal levels of HIF-1
and manifests minimal luciferase activity in normoxia (data not shown), transcriptional effects of ascorbate under normoxic conditions could not be studied. However, HRE-mediated luciferase reporter activity was strikingly induced by exposure of cells to CoCl2 and DFO, and this activity was reduced by 4060% by concurrent exposure of cells to ascorbate (Fig. 3A)
. Responses were assessed to graded hypoxia over the range 0.13.0% O2. In concordance with the lack of effect on induction of HIF-1
protein under hypoxia, ascorbate did not inhibit HRE-mediated transcription under stringent hypoxia (0.10.4% O2; Fig. 3B
). However, the transcriptional response induced by more moderate hypoxia (1.03.0% O2) was partially inhibited by 25 µM ascorbate, with strongest effects being observed at the higher O2 tensions. Indeed, the 1.8-fold induction of luciferase seen under 3.0% O2 was blocked completely in the presence of ascorbate (Fig. 3B)
.
|
(Fig. 4A)
under normoxia (Fig. 4B)
protein levels, ascorbate also had significant effects on the induction of VEGF by growth factors, substantially reducing the level of VEGF mRNA induced by both IGF-I and insulin (Fig. 4D)
|
| Discussion |
|---|
|
|
|---|
were specific to particular conditions, strongly suggesting that they are mediated by promotion of PHD activity. Thus, consistent with the absolute requirement for dioxygen as cosubstrate for this class of enzyme, no effect was observed under stringent hypoxia. Equally, ascorbate had no action in the presence of enzyme blockade by the 2-OG analogue MMOG or in the absence of a functional VHL. In contrast, marked effects were seen on cells exposed to Co(II), DFO, or moderate hypoxia, and on oncogenically activated normoxic cells. Effects on HIF transcriptional target genes demonstrate the biological importance of the effect and suggest that ascorbate may also promote FIH activity, although the current study cannot distinguish separate effects on the different HIF hydroxylases.
Previous studies of the biological action of ascorbate have focused on the collagen prolyl hydroxylase a functionally related set of Fe(II) and 2-OG dependent dioxygenases. The mechanism of action remains incompletely understood. Under normal turnover conditions ascorbate is not consumed stoichiometrically (6)
. However, ascorbate consumption can be promoted using artificial substrates that result in uncoupled decarboxylation of 2-OG. It is postulated that uncoupled cycles result in conversion of the enzyme-bound Fe(II) to Fe(III), that this self-oxidation occurs occasionally even under normal turnover conditions, and that the action of ascorbate is to reduce this to the active Fe(II) form within the enzyme active site (6)
. An alternative or additional possibility is that ascorbate might support the provision of Fe(II) within an intracellular pool that can replenish the active site with Fe(II). That such a mechanism may account, at least in part, for the effects we describe is suggested by several observations. First, we found that iron supplementation itself was able to reduce steady-state HIF-1
levels in normoxic cells in a manner similar to ascorbate. In previous work it has been shown that iron supplements antagonize the HIF-regulated induction of erythropoietin gene expression by cobaltous ions (12)
, most probably by increasing the availability of Fe(II) so as to compete out the incorporation of Co(II) at the hydroxylase active site. In the current work we found that ascorbate was also able to antagonize the effect of exposure to cobaltous ions and DFO. Taken together these observations are most compatible with an action of ascorbate to promote the availability of Fe(II) to the active site of the enzyme, although it is also possible that ascorbate itself chelates Co(II).
Whatever the precise mechanism, our findings indicate that ascorbate has large effects on the HIF system through promotion of HIF hydroxylase activity. This implies that without ascorbate or iron supplementation, enzyme activity is submaximal, and that under commonly used normoxic tissue culture conditions this enzyme activity is limiting for HIF proteolysis. Many previous studies have documented positive effects of oncogenic pathways on HIF in tissue culture cells (13, 14, 15)
. In keeping with this we found elevated levels of HIF-1
in normoxic OVCAR3 and PC3 cells, which carry loss-of-function mutations for p53 (16)
, and both p53 (9)
and PTEN (8)
, respectively, and in HS578T cells that express a constitutively activated H-ras (17)
. Effects of ascorbate and iron supplementation were particularly striking in these cells and under conditions of growth factor stimulation, amounting to complete abrogation of immunodetectable HIF-1
. These findings fit well with recent reports that oncogenically stimulated HIF-1
may accumulate in a nonhydroxylated form in the presence of oxygen (18)
and indicate that in the future it will be important to consider the availability of ascorbate when analyzing the effects of oncogenic stimulation of the HIF system.
The reasons why escape from hydroxylation is particularly evident under these conditions are unclear. Enhanced HIF-1
translation has been demonstrated after activation of the phosphatidylinositol 3'-kinase/TOR pathway by either activated pp60c-src (14)
or insulin (15)
, and it seems likely that in different cells other oncogenic and mitogenic signal pathways enhance HIF translation. Increased HIF translation might present an increased substrate load that exceeds the capacity of the HIF hydroxylases. Alternatively it is possible that during conditions of enhanced cellular growth the supply of Fe(II), ascorbate or both is impaired, effectively reducing hydroxylase activity. In support of this, it is well established that proliferating cells have a greater requirement for iron and manifest greater susceptibility to the toxicity of iron chelators (19)
.
In addition to the implications for the study of oncogenic activation of HIF in tissue culture cells, the findings could also be relevant to the regulation of the HIF system in vivo. At the systemic level, ascorbate is synthesized in the liver and kidney of most mammals (except primates, which lack the necessary gulonolactone oxidase activity) or obtained from dietary sources. At the cellular level ascorbate is transported into the cells by the Slc23a1 anion transporter (20) or replenished by the reduction of dehydroascorbate (21) . Whether ascorbate and/or iron deficiency affects activity of the HIF system in cancer in vivo will require additional investigation. Database predictions suggest that many additional members of this class of enzyme with as yet unknown functions, and ascorbate dependence, exist. Thus, effects on overall tumor growth could be determined by the summation of several biological effects, and may be difficult to predict, perhaps contributing to the uncertainties and controversies surrounding the effects of ascorbate on cancer progression and treatment (22) . Nevertheless, these new insights into the potential effects of ascorbate deficiency should enable a better understanding of its biological role in malignant and nonmalignant tissues.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
1 Supported by grants from the Wellcome Trust and Cancer Research (United Kingdom). R. R. R. was supported by a Rhodes Scholarship. ![]()
2 To whom requests for reprints should be addressed, at The Henry Wellcome Building of Genomic Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, United Kingdom. ![]()
3 The abbreviations used are: HIF, hypoxia-inducible factor; 2-OG, 2-oxoglutarate; VHL, von Hippel-Lindau; IGF, insulin-like growth factor; VEGF, vascular endothelial growth factor; DFO, desferrioxamine; MMOG, dimethyloxalylglycine; PHD, prolyl hydroxylase domain; FIH, factor inhibiting HIF; CBP, CREB binding protein; HRE, hypoxia response element; sn, small nuclear; TOR, target of rapamycin. ![]()
Received 11/19/02. Accepted 2/27/03.
| REFERENCES |
|---|
|
|
|---|
binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem., 275: 25733-25741, 2000.
in rat and human prostate cancer. Cancer Res., 58: 5280-5284, 1998.
expression under normoxia. J. Biol. Chem., 277: 42919-42925, 2002.
. J. Biol. Chem., 277: 40112-40117, 2002.This article has been cited by other articles:
![]() |
N. Patel, C. S. Gonsalves, P. Malik, and V. K. Kalra Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1{alpha} Blood, August 1, 2008; 112(3): 856 - 865. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Page, D. A. Chan, A. J. Giaccia, M. Levine, and D. E. Richard Hypoxia-inducible Factor-1{alpha} Stabilization in Nonhypoxic Conditions: Role of Oxidation and Intracellular Ascorbate Depletion Mol. Biol. Cell, January 1, 2008; 19(1): 86 - 94. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li and H. E. Schellhorn New Developments and Novel Therapeutic Perspectives for Vitamin C J. Nutr., October 1, 2007; 137(10): 2171 - 2184. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-L. Chen, F. Pistollato, D. J. Hoeppner, H.-T. Ni, R. D.G. McKay, and D. M. Panchision Oxygen Tension Regulates Survival and Fate of Mouse Central Nervous System Precursors at Multiple Levels Stem Cells, September 1, 2007; 25(9): 2291 - 2301. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. M. Vissers and R. P. Wilkie Ascorbate deficiency results in impaired neutrophil apoptosis and clearance and is associated with up-regulation of hypoxia-inducible factor 1{alpha} J. Leukoc. Biol., May 1, 2007; 81(5): 1236 - 1244. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Hewitson, B. M. R. Lienard, M. A. McDonough, I. J. Clifton, D. Butler, A. S. Soares, N. J. Oldham, L. A. McNeill, and C. J. Schofield Structural and Mechanistic Studies on the Inhibition of the Hypoxia-inducible Transcription Factor Hydroxylases by Tricarboxylic Acid Cycle Intermediates J. Biol. Chem., February 2, 2007; 282(5): 3293 - 3301. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Pan, K. D. Mansfield, C. C. Bertozzi, V. Rudenko, D. A. Chan, A. J. Giaccia, and M. C. Simon Multiple Factors Affecting Cellular Redox Status and Energy Metabolism Modulate Hypoxia-Inducible Factor Prolyl Hydroxylase Activity In Vivo and In Vitro Mol. Cell. Biol., February 1, 2007; 27(3): 912 - 925. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Fandrey, T. A. Gorr, and M. Gassmann Regulating cellular oxygen sensing by hydroxylation Cardiovasc Res, September 1, 2006; 71(4): 642 - 651. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Qutub and A. S. Popel A computational model of intracellular oxygen sensing by hypoxia-inducible factor HIF1{alpha}. J. Cell Sci., August 15, 2006; 119(Pt 16): 3467 - 3480. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Acker, J. Fandrey, and H. Acker The good, the bad and the ugly in oxygen-sensing: ROS, cytochromes and prolyl-hydroxylases Cardiovasc Res, July 15, 2006; 71(2): 195 - 207. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Oda, K. Hirota, K. Nishi, S. Takabuchi, S. Oda, H. Yamada, T. Arai, K. Fukuda, T. Kita, T. Adachi, et al. Activation of hypoxia-inducible factor 1 during macrophage differentiation Am J Physiol Cell Physiol, July 1, 2006; 291(1): C104 - C113. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Knowles, D. R. Mole, P. J. Ratcliffe, and A. L. Harris Normoxic Stabilization of Hypoxia-Inducible Factor-1{alpha} by Modulation of the Labile Iron Pool in Differentiating U937 Macrophages: Effect of Natural Resistance-Associated Macrophage Protein 1. Cancer Res., March 1, 2006; 66(5): 2600 - 2607. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. T. Jones, I. S. Trowbridge, and A. L. Harris Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate. Cancer Res., March 1, 2006; 66(5): 2749 - 2756. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Jokilehto, K. Rantanen, M. Luukkaa, P. Heikkinen, R. Grenman, H. Minn, P. Kronqvist, and P. M. Jaakkola Overexpression and Nuclear Translocation of Hypoxia-Inducible Factor Prolyl Hydroxylase PHD2 in Head and Neck Squamous Cell Carcinoma Is Associated with Tumor Aggressiveness Clin. Cancer Res., February 15, 2006; 12(4): 1080 - 1087. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Quintero, P. A. Brennan, G. J. Thomas, and S. Moncada Nitric Oxide Is a Factor in the Stabilization of Hypoxia-Inducible Factor-1{alpha} in Cancer: Role of Free Radical Formation Cancer Res., January 15, 2006; 66(2): 770 - 774. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Lu, C. L. Dalgard, A. Mohyeldin, T. McFate, A. S. Tait, and A. Verma Reversible Inactivation of HIF-1 Prolyl Hydroxylases Allows Cell Metabolism to Control Basal HIF-1 J. Biol. Chem., December 23, 2005; 280(51): 41928 - 41939. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Boddy, S. B. Fox, C. Han, L. Campo, H. Turley, S. Kanga, P. R. Malone, and A. L. Harris The Androgen Receptor Is Significantly Associated with Vascular Endothelial Growth Factor and Hypoxia Sensing via Hypoxia-Inducible Factors HIF-1a, HIF-2a, and the Prolyl Hydroxylases in Human Prostate Cancer Clin. Cancer Res., November 1, 2005; 11(21): 7658 - 7663. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H Maxwell Hypoxia-inducible factor as a physiological regulator Exp Physiol, November 1, 2005; 90(6): 791 - 797. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Wenger, D. P. Stiehl, and G. Camenisch Integration of Oxygen Signaling at the Consensus HRE Sci. Signal., October 18, 2005; 2005(306): re12 - re12. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Temes, S. Martin-Puig, B. Acosta-Iborra, M. C. Castellanos, M. Feijoo-Cuaresma, G. Olmos, J. Aragones, and M. O. Landazuri Activation of HIF-prolyl Hydroxylases by R59949, an Inhibitor of the Diacylglycerol Kinase J. Biol. Chem., June 24, 2005; 280(25): 24238 - 24244. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. van der Wel, A. Ercan, and C. M. West The Skp1 Prolyl Hydroxylase from Dictyostelium Is Related to the Hypoxia-inducible Factor-{alpha} Class of Animal Prolyl 4-Hydroxylases J. Biol. Chem., April 15, 2005; 280(15): 14645 - 14655. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Fang, C. Xia, Z. Cao, J. Z. Zheng, E. Reed, and B.-H. Jiang Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways FASEB J, March 1, 2005; 19(3): 342 - 353. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Fiala, O. S. Sohn, C.-X. Wang, E. Seibert, J. Tsurutani, P. A. Dennis, K. El-Bayoumy, R. S. Sodum, D. Desai, J. Reinhardt, et al. Induction of preneoplastic lung lesions in guinea pigs by cigarette smoke inhalation and their exacerbation by high dietary levels of vitamins C and E Carcinogenesis, March 1, 2005; 26(3): 605 - 612. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. McCarty Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380. [Abstract] [PDF] |
||||
![]() |
K. Salnikow, S. P. Donald, R. K. Bruick, A. Zhitkovich, J. M. Phang, and K. S. Kasprzak Depletion of Intracellular Ascorbate by the Carcinogenic Metals Nickel and Cobalt Results in the Induction of Hypoxic Stress J. Biol. Chem., September 24, 2004; 279(39): 40337 - 40344. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Acker and H. Acker Cellular oxygen sensing need in CNS function: physiological and pathological implications J. Exp. Biol., August 15, 2004; 207(18): 3171 - 3188. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Semenza Hydroxylation of HIF-1: Oxygen Sensing at the Molecular Level Physiology, August 1, 2004; 19(4): 176 - 182. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Cao, J. Fang, C. Xia, X. Shi, and B.-H. Jiang trans-3,4,5'-Trihydroxystibene Inhibits Hypoxia-Inducible Factor 1{alpha} and Vascular Endothelial Growth Factor Expression in Human Ovarian Cancer Cells Clin. Cancer Res., August 1, 2004; 10(15): 5253 - 5263. [Abstract] [Full Text] [PDF] |
||||
![]() |
|